Pipeline · VNQ-104Active studySynthetic mock data
VNQ-104 — FGFR2/3
Small molecule · Cholangiocarcinoma · Phase Ib
Modality
Small molecule
Target
FGFR2/3
Phase
Phase Ib
Toxicity flags
2
Mechanism
VNQ-104 is a small molecule engineered to engage FGFR2/3 with the goal of a clinically meaningful response in Cholangiocarcinoma. Currently in Phase Ib; next milestone: MTD declaration Q3.
Dose-escalation cohorts
| Dose | Cohort N | DLTs | Status |
|---|---|---|---|
| 50 mg QD | 6 | 0 | cleared |
| 100 mg QD | 6 | 1 | cleared |
| 150 mg QD | 9 | 1 | expanding |
| 200 mg QD | 0 | 0 | open |
Recent toxicity events
2 active| Date | Case | Grade | Term | Resolved |
|---|---|---|---|---|
| 2026-04-20 | P1b-CHO-019 | G2 | Hyperphosphatemia | Resolved |
| 2026-04-15 | P1b-CHO-024 | G1 | Diarrhea | Resolved |
Linked studies
Cross-links